Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report)'s stock price rose 7.7% during mid-day trading on Monday . The company traded as high as $9.70 and last traded at $9.93. Approximately 280,472 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 1,400,674 shares. The stock had previously closed at $9.22.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, May 29th. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. William Blair initiated coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating for the company. Needham & Company LLC lowered their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, Royal Bank Of Canada started coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, Ocular Therapeutix presently has a consensus rating of "Buy" and an average target price of $17.33.
Read Our Latest Stock Report on OCUL
Ocular Therapeutix Stock Down 2.0%
The firm has a market cap of $1.45 billion, a PE ratio of -7.95 and a beta of 1.42. The business's 50 day moving average price is $8.08 and its 200 day moving average price is $7.81. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.22 and a quick ratio of 10.14.
Insider Buying and Selling at Ocular Therapeutix
In other Ocular Therapeutix news, Director Richard L. Md Lindstrom purchased 10,000 shares of the firm's stock in a transaction dated Thursday, May 8th. The shares were purchased at an average cost of $6.96 per share, with a total value of $69,600.00. Following the completion of the purchase, the director owned 172,704 shares in the company, valued at approximately $1,202,019.84. This represents a 6.15% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Pravin Dugel sold 21,219 shares of the business's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the transaction, the insider owned 3,499,099 shares in the company, valued at $25,123,530.82. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,079 shares of company stock valued at $208,739. 2.30% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Ocular Therapeutix in the fourth quarter valued at approximately $28,000. Brooklyn Investment Group grew its holdings in Ocular Therapeutix by 151.5% in the 1st quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 3,155 shares in the last quarter. Atlas Capital Advisors Inc. acquired a new stake in shares of Ocular Therapeutix in the 4th quarter worth $43,000. AlphaQuest LLC purchased a new position in shares of Ocular Therapeutix during the 4th quarter worth $53,000. Finally, GAMMA Investing LLC raised its holdings in shares of Ocular Therapeutix by 6,760.0% during the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 8,112 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.
Ocular Therapeutix Company Profile
(
Get Free Report)
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Further Reading
Before you consider Ocular Therapeutix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.
While Ocular Therapeutix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
